Andrew Tsai
Stock Analyst at Jefferies
(0.59)
# 3,521
Out of 4,667 analysts
17
Total ratings
28.57%
Success rate
-11.62%
Average return
Main Sectors:
Stocks Rated by Andrew Tsai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRNS Marinus Pharmaceuticals | Downgrades: Hold | $5 → $0.5 | $0.31 | +61.24% | 1 | Oct 25, 2024 | |
| SRPT Sarepta Therapeutics | Initiates: Buy | $165 | $109.92 | +50.11% | 1 | Oct 21, 2024 | |
| RLMD Relmada Therapeutics | Upgrades: Buy | $3.5 → $13 | $2.86 | +354.59% | 2 | Sep 17, 2024 | |
| RAPP Rapport Therapeutics | Initiates: Buy | $35 | $22.38 | +56.39% | 1 | Jul 2, 2024 | |
| ANRO Alto Neuroscience | Initiates: Buy | $33 | $3.91 | +743.99% | 1 | Feb 27, 2024 | |
| VTGN Vistagen Therapeutics | Upgrades: Buy | $0.2 → $15 | $2.57 | +483.61% | 2 | Dec 7, 2023 | |
| LXRX Lexicon Pharmaceuticals | Initiates: Hold | $3 | $0.78 | +284.47% | 1 | Mar 7, 2023 | |
| ATHA Athira Pharma | Downgrades: Hold | $32 → $3 | $0.63 | +379.92% | 2 | Jun 23, 2022 | |
| BEKE KE Holdings | Upgrades: Overweight | $23 → $16 | $20.04 | -20.16% | 1 | Mar 16, 2022 | |
| VIGL Vigil Neuroscience | Initiates: Buy | $20 | $3.02 | +563.35% | 1 | Feb 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $55 → $70 | $84.80 | -17.45% | 2 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $1.54 | +1,658.50% | 1 | Sep 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $16 → $23 | $40.05 | -42.57% | 1 | Jun 1, 2020 |
Marinus Pharmaceuticals
Oct 25, 2024
Downgrades: Hold
Price Target: $5 → $0.5
Current: $0.31
Upside: +61.24%
Sarepta Therapeutics
Oct 21, 2024
Initiates: Buy
Price Target: $165
Current: $109.92
Upside: +50.11%
Relmada Therapeutics
Sep 17, 2024
Upgrades: Buy
Price Target: $3.5 → $13
Current: $2.86
Upside: +354.59%
Rapport Therapeutics
Jul 2, 2024
Initiates: Buy
Price Target: $35
Current: $22.38
Upside: +56.39%
Alto Neuroscience
Feb 27, 2024
Initiates: Buy
Price Target: $33
Current: $3.91
Upside: +743.99%
Vistagen Therapeutics
Dec 7, 2023
Upgrades: Buy
Price Target: $0.2 → $15
Current: $2.57
Upside: +483.61%
Lexicon Pharmaceuticals
Mar 7, 2023
Initiates: Hold
Price Target: $3
Current: $0.78
Upside: +284.47%
Athira Pharma
Jun 23, 2022
Downgrades: Hold
Price Target: $32 → $3
Current: $0.63
Upside: +379.92%
KE Holdings
Mar 16, 2022
Upgrades: Overweight
Price Target: $23 → $16
Current: $20.04
Upside: -20.16%
Vigil Neuroscience
Feb 1, 2022
Initiates: Buy
Price Target: $20
Current: $3.02
Upside: +563.35%
Sep 20, 2021
Maintains: Buy
Price Target: $55 → $70
Current: $84.80
Upside: -17.45%
Sep 1, 2021
Initiates: Buy
Price Target: $27
Current: $1.54
Upside: +1,658.50%
Jun 1, 2020
Assumes: Buy
Price Target: $16 → $23
Current: $40.05
Upside: -42.57%